Diabetics with multivessel, must keep waiting.

Original title: Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial. Reference: Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585

This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries > 70% in two or more major epicardial vessels but excluding injury of left coronary trunk with a minimum follow-up of 2 years.

Sirolimus-eluting stents or paclitaxel (interventionist selection) were used, use of abciximab and dual antiplatelet therapy was recommended for at least 1 year. For patients who received CABG arterial revascularization was also recommended. Medical treatment was completed with an LDL goal of

The primary end point was a composite of death from any cause, myocardial infarction and stroke. The major cardiovascular and cerebrovascular events at 30 days and 1 year, (added to previous revascularization), were the most important secondary end points.

Between April 2005 and 2010, 1,900 patients were randomized from the 3,309 eligible. The mean age was 63.1 ± 9.1, 83% had three-vessel disease and the average Syntax score was 26.2 ± 8.6.

Sirolimus eluting stents were used in 51% and paclitaxel eluting stents in 43% of PCI branch. We used other drug-eluting stents for the other 6%. The mean follow-up was 3.8 years. The primary end point occurred in 26.6% of the PCI group versus 18.7% in the CABG group with an absolute difference in favor of CABG of 7.9 points, (p = 0.005), at 5 years. The curves began to separate at 2 years follow-up.

Considering the components of the primary end point separately to five years, death from any cause was higher with PCI, (16.3% versus 10.9% p = 0.049), as well as myocardial infarction (13.9% versus 6 % p <0.001), the stroke, however, was higher with CABG, (5.2% versus 2.4% p = 0.03). Excess stroke with CABG occurred within 30 days of randomization. The major cardiovascular and cerebrovascular events, (secondary end point), at one year were higher with PCI, (16.8% versus 11.8% p = 0.004). This difference arose primarily from the increased repeat revascularization in the PCI group, (12.6% versus 4.8%, p <0.001).

The absolute difference in favor of CABG versus PCI in the primary end point was similar in the three subgroups of Syntax score. The result to five years comparing patients separately who received paclitaxel or sirolimus eluting stents versus CABG was identical.

Conclusion 

CABG is superior to PCI with drug-eluting stents to treat diabetic patients with multivessel disease.

Editorial Comment:

Substudies of diabetic patients of SYNTAX, ARTS or CARDia showed the difference between PCI and CABG but was mainly based on recurrence of revascularization, (the softest of all components). However, FREEDOM showed significant differences in death or myocardial infarction separately, even though the study had not statistical power to show it. We must await the development of new technologies that allow us to face percutaneous treatment of diabetic patients more effectively and above all, more securely. Perhaps functional revascularization with FFR and not the anatomical can reduce events in favor of angioplasty in diabetic patients, but there is no study available, even in randomization period, that can answer this question. The FREEDOM showed us probably the last Achilles heel of angioplasty

SOLACI.ORG

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...